MCLA-129

Phase 2Small molecule

BBetta Pharmaceuticals Co., Ltd.

MCLA-129 is one of 89 small molecule programs targeting Bispecific Antibody. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bispecific AntibodyActive, not recruiting

Non-Small Cell Lung CancerNot yet recruiting

Other Solid TumorsRecruiting

Patients With Advanced Solid TumorsRecruiting

Bispecific AntibodyPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Not yet recruiting

Other Solid TumorsPhase 2

Recruiting

Patients With Advanced Solid TumorsPhase 2

Recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Phase 3

10 2

Sigvotatug Vedotin

Pfizer

Phase 3

1 3

MCLA-129

BBetta Pharmaceuticals Co., Ltd.

Phase 2

1 4

BPI-7711

BBeta Pharma Shanghai

Phase 3

3 5

Remeron

OOrganon and Co

Preclinical

1 6

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 10

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1/2Active, not recruiting

Bispecific Antibody

NCT04868877

Q3 2028

Phase 2Not yet recruiting

Non-Small Cell Lung Cancer

NCT06885840

Q4 2028

Phase 1/2Recruiting

Other Solid Tumors

NCT04930432

Q3 2029

Phase 1/2Recruiting

Patients With Advanced Solid Tumors

NCT07448116

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.

Not yet recruiting·BBetta Pharmaceuticals Co., Ltd.·Phase 2·NCT06885840·100 enrolled

Patients With Advanced Solid Tumors1 trial

Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.

Recruiting·BBetta Pharmaceuticals Co., Ltd.·Phase 1/2·NCT07448116·164 enrolled

Bispecific Antibody1 trial

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Active, not recruiting·MMerus B.V.·Phase 1/2·NCT04868877·194 enrolled

Other Solid Tumors1 trial

Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

Recruiting·BBetta Pharmaceuticals Co., Ltd.·Phase 1/2·NCT04930432·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for MCLA-129. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MCLA-129 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MCLA-129. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Betta Pharmaceuticals Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBetta Pharmaceuticals Co., Ltd.

MCLA-129

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2028

Q4 2028

Q3 2029

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Patients With Advanced Solid Tumors1 trial

Bispecific Antibody1 trial

Other Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News